Your Gut Is Talking: The Peptides Behind Hunger and Fullness
Ghrelin says go, GLP-1 and PYY say stop. A tour of the small peptides that run appetite, and why they became drug targets.
The longest conversation in your body
Your gut is lined with cells that taste what passes through and send chemical messages to the brain and pancreas. Many of those messages are peptides. Together they decide when you feel hungry, when you feel full and how fast your stomach empties.
The cast
- Ghrelin is made mainly in the stomach. Levels rise before meals and drop after eating. It was identified in 1999 and is often called the hunger signal.
- Cholecystokinin (CCK) is released in the small intestine after fat and protein arrive. It triggers gallbladder contraction and helps you feel satisfied. It was one of the earliest gut peptides described, back in 1928.
- GLP-1 (glucagon-like peptide-1) comes from L-cells in the lower gut. It boosts insulin release only when blood sugar is high, slows stomach emptying and acts on brain regions that control appetite.
- PYY is released alongside GLP-1 and dampens appetite after meals.
Leptin, from fat tissue, is often listed with these but is a protein of 167 amino acids rather than a short peptide.
The problem with natural signals
Natural GLP-1 is destroyed within a few minutes by an enzyme called DPP-4. That is brilliant for a short, local message and useless as a medicine.
Drug designers solved this in two ways: by changing the molecule so DPP-4 cannot cut it, and by attaching a fatty-acid chain that makes it cling to albumin in the blood, which extends its life from minutes to days. This is the story behind modern once-weekly injectables.
From gut hormone to medicine
- Exenatide (2005) was the first GLP-1 receptor agonist approved. It came from the saliva of the Gila monster.
- Liraglutide and semaglutide are engineered human-GLP-1 analogues with the fatty-acid trick.
- Tirzepatide (2022) combines GIP and GLP-1 activity in a single molecule.
These medicines are prescription drugs with large trials behind them, including side effects such as nausea, and they are not suitable for everybody.
What not to conclude
A hormone that reduces appetite in a trial population does not mean any "gut peptide" sold online will do the same. Dose, purity, formulation and patient selection are all part of why the approved versions work, and why the lookalikes may not.
Key takeaways
- Ghrelin, CCK, GLP-1 and PYY form a layered appetite-control network.
- Natural GLP-1 lasts minutes; medicines are redesigned to last days.
- Clinical results belong to the specific, tested product, not to the whole molecule family.
Educational only. Not medical advice. Read the disclaimer.
